IL71504A - 20-spiroxanes and analogues having an open ring e,their manufacture and pharmaceutical compositions containing them - Google Patents

20-spiroxanes and analogues having an open ring e,their manufacture and pharmaceutical compositions containing them

Info

Publication number
IL71504A
IL71504A IL71504A IL7150484A IL71504A IL 71504 A IL71504 A IL 71504A IL 71504 A IL71504 A IL 71504A IL 7150484 A IL7150484 A IL 7150484A IL 71504 A IL71504 A IL 71504A
Authority
IL
Israel
Prior art keywords
spiroxanes
analogues
manufacture
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL71504A
Other languages
English (en)
Other versions
IL71504A0 (en
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of IL71504A0 publication Critical patent/IL71504A0/xx
Publication of IL71504A publication Critical patent/IL71504A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL71504A 1983-04-13 1984-04-11 20-spiroxanes and analogues having an open ring e,their manufacture and pharmaceutical compositions containing them IL71504A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
IL71504A0 IL71504A0 (en) 1984-07-31
IL71504A true IL71504A (en) 1987-07-31

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
IL71504A IL71504A (en) 1983-04-13 1984-04-11 20-spiroxanes and analogues having an open ring e,their manufacture and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (1) US4559332A (OSRAM)
EP (1) EP0122232B1 (OSRAM)
JP (1) JPS59231100A (OSRAM)
AR (4) AR241918A1 (OSRAM)
AT (1) ATE39256T1 (OSRAM)
AU (1) AU565017B2 (OSRAM)
CA (1) CA1220781A (OSRAM)
DD (2) DD251144A5 (OSRAM)
DE (2) DE3475622D1 (OSRAM)
DK (1) DK163988C (OSRAM)
ES (4) ES8602846A1 (OSRAM)
FI (1) FI77669C (OSRAM)
GR (1) GR81834B (OSRAM)
HU (1) HU191406B (OSRAM)
IE (1) IE57541B1 (OSRAM)
IL (1) IL71504A (OSRAM)
LU (1) LU91072I2 (OSRAM)
NL (1) NL300144I2 (OSRAM)
NO (1) NO159800C (OSRAM)
NZ (1) NZ207826A (OSRAM)
PH (1) PH19997A (OSRAM)
PT (1) PT78413B (OSRAM)
ZA (1) ZA842710B (OSRAM)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
JP2950616B2 (ja) * 1991-01-29 1999-09-20 塩野義製薬株式会社 トリテルペン誘導体
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
WO1996040257A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US5981744A (en) 1995-12-11 1999-11-09 G. D. Searle And Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
EP1167381A3 (en) * 1995-12-11 2004-09-29 G.D. Searle & Co. Process for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and Intermediates useful therein
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
CN100369927C (zh) * 1996-12-11 2008-02-20 G·D·瑟尔公司 9,11-环氧甾族化合物和其中有用的中间体的制备方法
EP1000547A4 (en) * 1998-05-29 2004-05-06 Kyowa Hakko Kogyo Kk METHOD FOR PRODUCING LIQUID SPICES WITH THE TASTE OF VEGETABLES MARINATED IN SALTED RICE BRANCH
EP1126880A2 (en) * 1998-11-06 2001-08-29 G.D. SEARLE & CO. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
KR20010102965A (ko) * 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및담즙산 격리제의 병용
PT1140189E (pt) 1998-12-23 2003-09-30 Searle Llc Combinacoes de inibidores do transporte do acido biliar ileal e de derivados do acido fibrico para indicacoes cardiovasculares
AU776664B2 (en) * 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
ES2203239T3 (es) 1998-12-23 2004-04-01 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de agentes secuestrantes de acidos biliares para indicaciones cardiovasculares.
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
WO2001041535A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
ES2240209T3 (es) * 1999-12-08 2005-10-16 Pharmacia Corporation Composiciones de eplerenona nanoparticulada.
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
JP2003516414A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション より高い溶解速度を示すエプレレノン結晶形
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6586434B2 (en) 2000-03-10 2003-07-01 G.D. Searle, Llc Method for the preparation of tetrahydrobenzothiepines
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
CA2415789A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
BR0115245A (pt) * 2000-10-30 2005-05-10 Pharmacia Corp 11 alfa-hidroxilase e óxido redutase de aspergillus ochraceus
PT1343530E (pt) * 2000-11-09 2007-09-25 Astrazeneca Ab Composição farmacêutica oral contendo um copolímero de blocos
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
US7015210B2 (en) * 2001-12-12 2006-03-21 Pharmacia Corporation Methods of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
KR20040107481A (ko) * 2002-03-18 2004-12-20 파마시아 코포레이션 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물
CN1642557A (zh) * 2002-03-18 2005-07-20 法玛西雅公司 醛固酮受体拮抗剂与烟酸或烟酸衍生物的组合
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
PL373189A1 (en) * 2002-03-22 2005-08-22 Pharmacia & Upjohn Company Llc Process to prepare eplerenone
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2495412A1 (en) * 2002-08-16 2004-02-26 Pharmacia & Upjohn Company 5 androsten-3.beta.-ol steroid intermediates and processes for their preparation
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
PL376919A1 (pl) * 2002-11-06 2006-01-09 Pharmacia & Upjohn Company Llc Sposoby wytwarzania 7-karboksy-podstawionych steroidów
TWI280133B (en) * 2002-11-07 2007-05-01 Upjohn Co Process for preparing C-7 substituted steroids
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2005092913A1 (en) * 2004-03-22 2005-10-06 Pharmacia & Upjohn Company Llc Improved process for the preparation of 9,11 epoxy steroids
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
EP2124959A4 (en) * 2006-12-21 2011-09-14 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
AR076707A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5913136B2 (ja) * 2010-02-08 2016-04-27 プレーリー ファーマシューティカルズ、エルエルシー 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法
WO2011141456A1 (en) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
KR20150119109A (ko) 2013-02-14 2015-10-23 노파르티스 아게 Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
EP3009443B1 (en) 2014-10-17 2018-09-12 INDUSTRIALE CHIMICA S.r.l. Process for the preparation of 7alfa-(methoxycarbonyl)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactone, a useful intermediate for the synthesis of molecules with pharmacological activity
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
HU191406B (en) 1987-02-27
ES8705459A1 (es) 1987-05-01
ATE39256T1 (de) 1988-12-15
FI841400L (fi) 1984-10-14
IE57541B1 (en) 1992-10-07
IL71504A0 (en) 1984-07-31
PT78413A (en) 1984-05-01
EP0122232A1 (de) 1984-10-17
DK163988C (da) 1992-09-21
AR241918A1 (es) 1993-01-29
IE840906L (en) 1984-10-13
ES8705461A1 (es) 1987-05-01
NL300144I1 (nl) 2004-06-01
DD251144A5 (de) 1987-11-04
JPS59231100A (ja) 1984-12-25
NZ207826A (en) 1986-07-11
DK189484A (da) 1984-10-14
PT78413B (en) 1986-08-22
US4559332A (en) 1985-12-17
DK163988B (da) 1992-04-27
LU91072I2 (fr) 2004-04-07
DE3475622D1 (en) 1989-01-19
FI77669B (fi) 1988-12-30
ES531517A0 (es) 1985-12-01
EP0122232B1 (de) 1988-12-14
CA1220781A (en) 1987-04-21
ES544769A0 (es) 1987-05-01
NO159800B (no) 1988-10-31
DE122004000012I1 (de) 2012-05-16
FI841400A0 (fi) 1984-04-09
NL300144I2 (nl) 2004-06-01
AR242222A1 (es) 1993-03-31
PH19997A (en) 1986-08-28
JPH0212479B2 (OSRAM) 1990-03-20
ES544770A0 (es) 1987-05-01
ES8705460A1 (es) 1987-05-01
ES544768A0 (es) 1987-05-01
AR242221A1 (es) 1993-03-31
AU565017B2 (en) 1987-09-03
DD233375A5 (de) 1986-02-26
FI77669C (fi) 1989-04-10
DK189484D0 (da) 1984-04-12
ES8602846A1 (es) 1985-12-01
ZA842710B (en) 1984-11-28
AR242223A1 (es) 1993-03-31
DE122004000012I2 (de) 2006-06-08
NO159800C (no) 1989-02-08
AU2685384A (en) 1984-10-18
GR81834B (OSRAM) 1984-12-12
NO841465L (no) 1984-10-15

Similar Documents

Publication Publication Date Title
IL71504A (en) 20-spiroxanes and analogues having an open ring e,their manufacture and pharmaceutical compositions containing them
DE3468030D1 (en) 13-alpha-alkyl gonanes, their preparation and pharmaceutical compositions containing them
IL65056A0 (en) Imidazodiazepines,their manufacture and pharmaceutical compositions containing them
IL60474A (en) Cyclopeptides of the somatostatin type,their manufacture and pharmaceutical compositions containing them
IL72572A0 (en) Peptides,their preparation and pharmaceutical compositions containing them
IL70365A0 (en) Substituted tetrapeptides,their manufacture and pharmaceutical compositions containing them
IL73951A0 (en) 2-phenyl-imidazoles,their preparation and pharmaceutical compositions containing them
IL71475A0 (en) N-aryl-alpha-amino-carboxamides,their preparation and pharmaceutical compositions containing them
IL72725A (en) Stigmast-3beta-yloxyphosphorylcholine and analogues thereof,their manufacture and pharmaceutical compositions containing them
IL71481A0 (en) Substituted indeno-pyridazinones,their preparation and pharmaceutical compositions containing them
IL71419A0 (en) Phenylaminobenzenealkanols,their preparation and pharmaceutical compositions containing them
IL72219A0 (en) Peptides,their production and pharmaceutical compositions containing them
IL68576A0 (en) Azepinoindoles,their production and pharmaceutical compositions containing them
IL67284A (en) N-substituted-2-pyridylindoles,their manufacture and pharmaceutical compositions containing them
IL73471A (en) N,n-di-n-propyl-4-hydroxy-3-methanesulfonamido-phenethylamine and pharmaceutical compositions containing them
IL72123A0 (en) Substituted phenylalkyl-piperazinyl-and homopiperazinyl-propyl-ureas and-thioureas,their preparation and pharmaceutical compositions containing them
IL72307A (en) Pyridinyl-2-pyrimidinamines,their preparation and pharmaceutical compositions containing them
IL71110A0 (en) Azolylmethylcycloalkanes,their preparation and pharmaceutical compositions containing them
IL71661A0 (en) 4-phenyl-tetrahydro-furano-pyridines,their preparation and pharmaceutical compositions containing them
IL70229A0 (en) 2-penem derivatives,their manufacture and pharmaceutical compositions containing them
IL67813A0 (en) Benzothienylallylamines,their production and pharmaceutical compositions containing them
IL72891A0 (en) Phenethylamine derivatives,their manufacture and pharmaceutical compositions containing them
IL70873A0 (en) D-homosteroids,their manufacture and pharmaceutical compositions containing them
IL71078A0 (en) Benzamide derivatives,their manufacture and pharmaceutical compositions containing them
IL70273A0 (en) Acridanone derivatives,their manufacture and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
EXP Patent expired